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Abstract We show that the levels and activity of the oc-subunits 
of Gs and G¡ proteins in plasma membrane of GH4C1 cells are 
regulated by the availability of mevalonate (MVA), and not by 
changes in cholesterol cell content. Changes in the levels of 
MVA, induced by modulation of 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase, determine the amount of 
both membrane-bound Ga-subunits, which correlated with the 
activity of their effector adenylyl cyclase. Lipoprotein deficient 
serum (LPDS) decreases cholesterol content and increases both 
HMG-CoA reductase activity and Ga-subunits in the membrane. 
Cholesterol and 25-hydroxycholesterol (25-HC) each repress 
HMG-CoA reductase and diminish Ga-subunit levels. However, 
while cholesterol cell content is also decreased by 25-HC, 
exogenous cholesterol increases it. In addition, the decrease of 
both Ga-subunits is reversed by the presence of MVA. This 
regulation appears to be mediated by nonsterol products 
generated from MVA. We assume that the first is the prenylation 
of the y-subunits, since the attachment of Ga-subunits to the 
membrane is dependent on this modification. However, as neither 
of our treatments completely abolished protein prenylation, we 
conclude that another MVA derivative is required in addition to 
prenyl residues to the presence and activity of a-subunits in the 
membrane. 
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1. Introduction 
Guanine nucleotide-binding regulatory proteins (G-pro-
teins) are heterotrimers composed of subunits referred to as 
a, ß and y. These proteins are associated with the inner face of 
the plasma membrane, where they act as transductors between 
membrane-bound receptors and effectors, i.e. enzymes and ion 
channels. Probably the system studied in most depth is that of 
adenylyl cyclase (AC). This system is positively and negatively 
regulated by Gs and G¡ proteins respectively [1]. 
A growing body of evidence indicates that several posttran-
slational modifications are required for the location of G-pro-
teins in the inner surface of the membrane and for their ac-
tivity. Covalent lipid modifications are found in both the a-
and y-subunits of G-proteins. These modifications establish 
the interaction of the protein with the membrane. The a-sub-
units of Gs and Gq subfamilies are palmitoylated [2,3] and 
members of the G¡ subfamily are both palmitoylated and 
myristoylated [2]. All of the isolated G-protein y-subunits 
have been reported to be isoprenylated. Protein isoprenylation 
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is a posttranslational modification in which a farnesyl or ger-
anylgeranyl isoprenoid is attached to a carboxyl-terminal cys-
teine residue of the consensus CAAX domain (C, cysteine; A, 
aliphatic amino acid; X, any amino acid) [4]. Retinal yi and 
brain y2 proteins have been shown to contain farnesyl [5,6] 
and geranylgeranyl [7,8] modifications in the C-terminal cys-
teine residues, respectively. The carboxyl-terminal posttransla-
tional modifications of G-protein y-subunits are important 
determinants of the subcellular location of the G-subunits. 
ß- and y-subunits do not dissociate under physiological con-
ditions and thus behave essentially as a monomer required for 
efficient coupling of Ga-subunits to cell surface receptors, and 
function as membrane anchors for the a-subunits [9,10]. Con-
sistent with that, the substitution of the modified cysteine by 
serine in y2 redistributes the subcellular location of both ß-
[11] and a- [12] subunits. There is also evidence that suggests 
the involvement of the prenyl group in protein-protein inter-
actions [13,14]. The biological significance of this modification 
is not fully understood, but in the best known case, that of the 
ras oncogene product (p21ras), the farnesyl moiety is required 
for the transforming activity of the protein and for its mem-
brane anchorage [15-17]. 
It is well known that mevalonate (MVA) availability is 
required for growth in mammalian cells, besides being the 
key metabolite in the biosynthesis of cholesterol and a variety 
of non-sterol isoprenoid compound derivatives [18], among 
which are the prenyl residues for posttranslational modifica-
tion. The formation of MVA, catalyzed by 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase, is the 
key regulatory step of this pathway. In cultured mammalian 
cells, the activity of this enzyme is controlled by a feedback 
mechanism mediated by cholesterol cell content. In the ab-
sence of exogenous cholesterol the cells synthesize their own 
MVA and cholesterol, maintaining high levels of HMG-CoA 
reductase, while in the presence of exogenously added choles-
terol or of its oxygenated derivative 25-hydroxycholesterol 
(25-HC), the activity of the enzyme is reduced, thereby turn-
ing off the MVA and cholesterol cellular synthesis [19]. 
Although there is an extensive literature concerning the 
relationships between MVA-derived non-sterol compounds, 
cell proliferation and G-proteins, mainly using inhibitors of 
HMG-CoA reductase (statins), which completely suppress 
prenyl synthesis, little attention has been focused on the rela-
tionship between MVA and cholesterol metabolism and G-
proteins in physiological and basal conditions. 
We have shown in a previous report [20] that lovastatin, a 
competitive inhibitor of HMG-CoA reductase, decreases the 
amount of G-protein a-subunits associated with the plasma 
membrane in GH4C1 cells, a clonal rat pituitary cell strain. 
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The effect of lovastatin was reversed by exogenously added 
MVA, suggesting that the cause of this decrease is the lack of 
prenylation of the y-subunit. In the present study, experiments 
were carried out to determine whether changes in cholesterol 
cell content and/or M V A availability, induced by the avail-
ability of the former, could regulate the amount of G-proteins 
in the cell membrane in a more physiological way. In order to 
get a mechanistic approach of the effect of cholesterol on this 
parameter, we have used cholesterol and 25-HC instead of 
lovastatin for the study of the changes in membrane localiza-
tion of the GTP-binding proteins ccs and oc¡ in GH4C1 cells, as 
well as in their regulated effector adenylyl cyclase. 
In the present study we demonstrate that the localization 
and activity of G a s and Goc¡ in the plasma membrane were 
significantly decreased by inhibiting H M G - C o A reducíase and 
not by changes in free cholesterol content. Since the synthesis 
of M V A is regulated by cell cholesterol content, this strongly 
suggests that cholesterol, not directly, but through M V A 
synthesis, controls the presence and the activity of Gocs and 
Got; in the plasma membrane. Therefore, in a non-stimulated 
situation, the rate of M V A synthesis is limiting for some sig-
nal transduction pathways via G-proteins. 
2. Materials and methods 
2.1. Materials 
Culture media, sera and antibiotic were from Gibco (Grand Island, 
NY), and culture flasks and plates were purchased from Nunc (Ros-
kilde, Denmark). Antibodies against GCL, and Ga¡ were from Calbio-
chem (Palo Alto, CA). [o>32P]ATP, [3H]cAMP and [14C]HMG-CoA 
were from New England Nuclear (Boston, MA). All other reagents 
were obtained from Sigma (St. Louis, MO), Calbiochem or Bio-Rad 
and were of the maximal purity available. 
2.2. Isolation of lipoprotein-deficient serum 
Lipoprotein-deficient serum (LPDS) was prepared from fetal bovine 
serum (FBS) by ultracentrifugal flotation in potassium bromide [21] at 
1.210 g/ml density [22]. After extensive dialysis against 50 mM Tris, 
150 mM NaCl, 0.01% EDTA, pH 7.4. LPDS was sterilized by passage 
through a Millipore filter (Millex-GV 0.22 urn) and kept frozen at 
-20°C. 
2.3. Cell culture and cellular treatments 
Pituitary GH4C1 cells were grown in monolayers as previously de-
scribed [23] in Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% FBS in a water saturated atmosphere of 5% CO2 
and 95% air. 
At the beginning of the experiments, the cells were rinsed with 
normal saline and incubated with fresh medium containing 10% 
FBS or 10% LPDS for 24 h at 37°C. After this preincubation, the 
cells were rinsed and incubated with the different media for 48 h as 
described in the figure legends. 
Cholesterol (5 mg/ml) and 25-hydroxycholesterol (5 mM) were dis-
solved in ethanol. Before adding, ethanol was evaporated under N2 
flow. Mevalonolactone was diluted in water (10 mM). All of these 
compounds were added to the medium supplemented with 10% 
LPDS. 
2.4. Immunoblotting of Ga3 and Ga¡ 
Cell pellets were homogenized in buffer (50 mM Tris-HCl, pH 7.5, 
5 mM EDTA, containing 5 mg/ml soybean trypsin inhibitor, 0.1 mM 
phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin, 
1 mg/ml benzamidine) by three times freezing in liquid nitrogen and 
thawing at 32°C. Nuclei and unbroken cells were pelleted by centri-
fugation at 500 Xg for 2 min, and the resulting supernatant was then 
centrifuged at 50000Xg for 15 min. Membrane pellets were resus-
pended in homogenizing buffer at a concentration of 1-2 mg/ml of 
protein. 10 ug of membrane protein was fractionated by SDS-PAGE 
and transferred to nitrocellulose membrane as described by Towbin et 
al. [24]. The nitrocellulose membranes were incubated with either anti-
Gas or anti-Ga¡ antibody, and the immunoreactive bands were de-
tected by the use of a horseradish peroxidase-coupled secondary anti-
body and the enhanced chemiluminescence (ECL) system (Amer-
sham). 
2.5. Measurement of cholesterol 
The concentration of cellular free cholesterol was determined as 
previously described [25]. Lipids were extracted from the cells with 
chloroform-methanol (2:1), chloroform was evaporated under N2 
flow and the enzymatic reagent added. Values are expressed as ug 
of free cholesterol per mg cell protein. 
2.6. HMG-CoA reducíase activity 
HMG-CoA reductase activity of freshly isolated cell lysates was 
measured with [14C]HMG-CoA as the substrate during a 2-h reaction 
essentially as described elsewhere [26]. Activity was calculated as pmol 
of mevalonolactone formed per min per mg cell protein. 
2.7. Adenylyl cyclase assay 
Assays were performed by incubation at 32°C for 10 min in a final 
volume of 50 ul of a mixture containing 25 mM Tris-HCl, pH 7.6, 0.1 
mM [a-32P]ATP (approx. 5 X106 cpm/assay), 2.0 mM MgCl2, 1.0 mM 
EDTA, 1.0 mM [3H]cAMP (approx. 15 000 cpm/assay), 0.1% bovine 
serum albumin, a nucleoside triphosphate regenerating system (20 
mM creatine phosphate, 26 U/ml creatine kinase, 25 U/ml myoki-
nase), 10 ul homogenate and 20 uM GTP. After 10 min of incubation, 
the reaction was stopped by addition of 100 ul of stopping solution 
(10 mM ATP, 10 mM cAMP and 1% sodium dodecyl sulfate (SDS)). 
The [32P]cAMP formed was measured by a modification [27] of the 
method of Salomon et al. [28]. Values are expressed as pmol of cAMP 
generated per min per mg cell protein. 
2.8. Measurement of cell protein 
Proteins were determined as described by Bradford [29], using bo-
vine serum albumin as standard. 
3. Results 
3.1. Effect of LPDS, cholesterol and 25-hydroxycholesterol on 
G-protein a-subunits 
First of all, we tried to see the effect of LPDS on Gccs and 
Got; protein membrane levels in GH4C1 cells. As shown in 
Fig. 1, immunoblott ing demonstrated that incubation of the 
175 
FBS LPDS FBS LPDS 
Fig. 1. Effect of LPDS on the levels of membrane-bound Ga-subu-
nits. Cells were preincubated with whole serum (10% FBS) or chol-
esterol-depleted by incubation in medium supplemented with 10% 
LPDS for 72 h. Membrane from cells was prepared and solubilized, 
and polyacrylamide gel electrophoresis, immunoblotting, and auto-
radiography were carried out as described in Section 2. Data shown 
are the means ± S.E. of four independent experiments performed in 
duplicate. ***P< 0.001. Representative immunoblot bands of both 
as- and otj-subunits appear below each group of columns. 
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Fig. 2. Treatment with cholesterol (A) and 25-HC (B) decreases 
Gas and Ga¡ protein levels in plasma membranes. Cells were chol-
esterol-depleted by preincubation in medium supplemented with 
10% LPDS for 24 h. Then, the media were removed and replaced 
with fresh media with 10% LPDS containing increasing concentra-
tions of cholesterol (A) or 25-HC (B) for the following 48 h. Immu-
noblotting of membrane proteins was assayed as described in Sec-
tion 2. Data shown are the means ± S.E. of four independent 
experiments performed in duplicate. ***P< 0.001. Representative im-
munoblot bands of both a,,- and a¡-subunits appear below the plot. 
cells with LPDS for 72 h markedly increased the amount of 
both as- and a¡-subunits in plasma membrane, this increase 
being about 150% of that of controls incubated in normal 
FBS. 
LPDS is a well known acceptor of cholesterol from the cells 
that decreased the cholesterol cell content (Table 1). Conse-
quently cells responded with an increase in HMG-CoA reduc-
íase activity (Table 1). 
In order to distinguish whether the effect of LPDS on ocs-
and oii-subunits could be due to the decrease in cholesterol cell 
content or to the increase in MVA synthesis, we studied the 
effect of exogenously added cholesterol, and also the effect of 
oxygenated derivative 25-hydroxycholesterol (25-HC) on the 
cellular levels of cholesterol and HMG-CoA reductase (Table 
1). While exogenously added cholesterol increased the choles-
terol content and decreased the HMG-CoA activity, 25-HC 
decreased both cholesterol and enzyme activity. 
When the amount of both Ga-subunits (ocs and ce¡) in the 
plasma membrane were determined in cells incubated with 
increasing concentrations of either exogenous cholesterol 
(Fig. 2A) or 25-HC (Fig. 2B) for 48 h, a significant decrease 
in both subunits were observed in a dose-related manner with 
both treatments, returning to the values of control cells incu-
bated with whole serum. 
In all cases, treatment of cells either with LPDS, 25-HC or 
cholesterol did not alter the synthesis of total proteins as 
determined using [3H]leucine (data not shown). 
3.2. Effect of LPDS, cholesterol and 25-hydroxycholesterol on 
AC activity 
Since AC activity is highly dependent on the levels and 
association state of ocs and a¡ in plasma membrane, we exam-
ined how the changes in ocs and oc¡ proteins promoted by 
cellular cholesterol manipulation affect the activity of their 
effector AC. LPDS significantly increased AC activity (Fig. 
3A), while cholesterol and 25-HC decreased AC activity in a 
dose-related manner (Fig. 3B). These results correlate with the 
decrease in the amount of ocs and a¡ subunits in plasma mem-
brane. 
3.3. MVA but not cholesterol suppresses the effect of 
25-hydroxycholesterol on G-proteins and AC activity 
The results observed on o^ and oc¡, promoted by LPDS, are 
not related to changes in cholesterol cell content, but rather to 
the rate of MVA synthesis, which is a consequence of HMG-
CoA reductase activity. To prove that the lack of MVA syn-
thesis, and not cholesterol, was the cause of the decrease in a¡¡ 
and cCj in the membrane, we directly examined the ability of 
exogenous MVA and cholesterol to overcome the inhibitory 
effect of 25-HC. When cells were incubated for 48 h with 25-
HC in the presence of either MVA or cholesterol, only exo-
genous MVA was able to counteract the effect of 25-HC on Og 
and CCj levels in plasma membrane (Fig. 4), while cholesterol 
did not have any effect. Similarly, MVA addition to the media 
reversed the inhibitory effect of 25-HC on AC while choles-
terol did not suppress the effect of the inhibitory metabolite 
(Fig. 5). 
4. Discussion 
In the present study on GH4Ci cells, we demonstrate that 
Table 1 
Effect of LPDS, cholesterol and 25-hydroxycholesterol on cholesterol cell content and HMG-CoA reductase activity 
Cholesterol content (|xg/mg protein) HMG-CoA reductase (pmol/min/mg protein) 
FBS 
LPDS 
LPDS+cholesterol (50 ug/ml) 
LPDS+25-HC (2.5 uM) 
20.08 ±2.8 
11.92± 1.2*** 
50.52 ±5.3+++ 
8.67 ±2.3+ 
34 ±2.2 (100) 
280 ±17 (730)** 
31 ±3.5 (91) 
28 ± 3 (82) 
Cells were preincubated with medium supplemented with 10% FBS or 10% LPDS for 24 h. The media were removed and replaced with fresh media 
with 10% FBS, or 10% LPDS in the absence or presence of the following additions: cholesterol or 25-hydroxycholesterol (25-HC). Enzyme 
activities were performed as described in Section 2. Values shown are the means ± S.E. of three independent determinations carried out in duplicate. 
Numbers in parentheses are percentages of control. ***f<0.001 compared to FBS; +0.05 > P > 0.01; +++i><0.001 compared to LPDS. 
A. Chiloeches et al.lFEBS Letters 401 (1997) 68-72 71 
Cholesterol (pg/ml) 
1.2 2.5 5 
25-hydroxycholesterol (MM) 
Fig. 3. Effect of LPDS (A), cholesterol and 25-HC (B) on AC activ-
ity. Cells were preincubated with medium supplemented with 10% 
FBS or 10% LPDS for 24 h. The media were removed and replaced 
with fresh media with 10% FBS or LPDS alone (A), or 10% LPDS 
containing increasing concentration of cholesterol or 25-HC. AC ac-
tivity was carried out as described in Section 2. Data shown are the 
means ±S.E. of four independent experiments performed in dupli-
cate. "0.01>P>0.001; »*P<0.001. 
25-HC - + + + 
Cholesterol — — + — 
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Fig. 5. The addition of MVA reverts the effect of 25-HC on AC ac-
tivity. AC activity was assayed in cells treated as described in Fig. 
4. 25-HC = 2.5 uM 25-hydroxycholesterol; cholesterol, 50 ug/ml; 
MVA = 250 uM mevalonate. Each bar represents the means ±S.E. 
of four determinations carried out in duplicate. ***P< 0.001. 
the location in plasma membrane and the activity of the Ga s 
and GOj are regulated by a MVA-dependent mechanism, i.e. 
by the amount of MVA itself or by a non-steroid derivative. 
This type of regulation would be of physiological significance 
since Gs and G¡ are associated with the activity of AC and to 
the generation of cAMP, as well as with other signal trans-
duction pathways. Moreover, the rate of MVA synthesis is 
regulated by the amount of free cholesterol [18], and there-
fore, changes in cholesterol cell content would regulate the 
activity of Gs and G¡ proteins indirectly. 
Our data clearly indicate that incubation of GH4Ci cells 
with LPDS decreases the cholesterol cell content by 50% 
and increases the amount of ocs- and a¡-subunits in the cell 
membrane and, consequently, their basal AC activity. 
Although Ga¡ is also increased in cells incubated with 
LPDS we only observed stimulation on AC activity. One pos-
25-HC 
Cholesterol 
Mevalonate 
a 
a 
— — — + 
s1v 
s 2 ' 
—a¡ 
Fig. 4. MVA but not cholesterol recovers the Gas and Gctj protein 
levels in membranes of 25-HC-treated cells. Cells were preincubated 
with medium supplemented with 10% LPDS for 24 h. The media 
were removed and replaced with fresh media with 10% LPDS alone 
or 10% LPDS plus 2.5 uM 25-HC in the absence or presence of 50 
ug/ml of cholesterol or 50 uM MVA for the following 48 h. Immu-
noblotting of membrane proteins was carried out as described in 
Section 2. Each bar represents the means ± S.E. of duplicate deter-
minations from four experiments. ***P< 0.001. Panels below each 
group of columns are representative immunoblots using the indi-
cated antibodies. 
sible explanation is that not all mammalian AC are subject to 
inhibitory regulation by a¡. Ga¡ inhibits types I and V AC 
[30,31], but these isoforms are not present in GH4C1 cells (L. 
Birnbaumer, personal communication). By contrast, a high 
concentration of oc¡ could be stimulating other isoforms of 
AC. In support of this hypothesis, Federman et al. [32] noted 
that activation of Ga¡ resulted in conditional activation (and 
not inhibition) of type II AC. 
These changes can be attributed to the increase in the ac-
tivity of HMG-CoA reducíase and the consequent increase in 
MVA levels, because they were suppressed by the addition of 
two inhibitors of MVA synthesis: cholesterol itself and 25-
HC. Since the cholesterol cell content was increased by exo-
genous cholesterol, and decreased by 25-HC, it seems to in-
dicate that the effect of LPDS on the amount of Ga-subunits 
in plasma membrane is independent of the cholesterol cell 
content. On the other hand, since the addition of MVA, but 
not cholesterol, was able to suppress the inhibitory effects of 
25-HC over LPDS, it can be suggested that MVA itself, or a 
non-sterol MVA derivative, is responsible for the steady-state 
of Gs and G¡ in the cell membrane. 
One mechanism by which MVA is limiting for the localiza-
tion of as- and a;-subunits in plasma membrane is due to the 
fact that the association of Ga-subunits with the membrane is 
dependent on prenylation and/or further carboxy-terminal 
processing of y-subunits, which are indispensable for the 
high affinity of ßy for a-subunits [33]. We assume that the 
changes in the amount of a-subunits in the membrane, in-
duced by the presence or absence of sterols, could be caused 
by the amount of prenyl residues derived from endogenous 
MVA. However, although it has been shown that a lack of 
prenylation of y-subunits either by mutation [11] or by inhibi-
tion of prenyl synthesis in cells [12], produces non-prenylated 
proteins that remain cytosolic, it has not been shown that an 
increase in MVA causes a parallel increase in the amount of 
prenylated proteins and/or their location in plasma mem-
brane. By contrast, Rilling et al. [34] have demonstrated 
that high MVA levels increase the lipid synthesis, without 
increasing the prenylation of one specific protein. On the 
other hand, Lutz et al. [35] have demonstrated, in rabbit re-
ticulocyte lysates, that the synthesis of geranylgeranyl pyro-
phosphate (GGPP) and farnesyl pyrophosphate (FPP), the 
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precursors of the prenyl residue in y-subunits and p21 r a s p ro-
tein respectively, is product regulated. The synthesis of G G P P 
and FPP is several-fold higher in the presence of a prenyl 
acceptor (protein) than in its absence, without changes in 
the pools of prenyl PPs. If this regulation of the prenyl resi-
dues occurs in whole cells, it makes it unlikely that the in-
crease in prenyl residues from endogenous or exogenous 
M V A could be the regulatory factor that increases the 
amount of oc-subunits in the cell membrane. This is also sug-
gested by the fact that we observe a decrease in ot-subunits in 
the membrane in the presence of cholesterol and/or 25-HC, a 
situation in which it has been shown that protein prenylation 
is not inhibited and the synthesis of total proteins is not mod-
ified [36]. Together, all these facts seem to indicate that the 
effect of LPDS on the amount of oc-subunits in the cell mem-
brane should be caused by some other M V A derivative in 
addition to the increase in prenyl residues, but the mechanism 
of this synergistic regulation remains to be elucidated. 
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